RMAT designation is based on promising Phase 2 clinical data demonstrating NG01’s potential to reduce disability and ...

Early studies of biotin as a treatment for multiple sclerosis (MS) were promising, showing that it was well tolerated and brought sustained reversal of MS-related disability. More recent studies, ...

People with late-onset MS, who experience their first symptoms after age 50, tend to have faster disability progression, ...

Depression screening predicts subsequent disability progression in people with primary progressive multiple sclerosis.

A study questioned the use of brain volume loss as a clinical trial endpoint in PPMS after finding a weak link to disability ...

"After considering the association between higher number of pregnancies and delay in progressive MS, together with each patient’s current disease phase and activity, MS itself may not represent a main ...

NEW YORK--(BUSINESS WIRE)--The Tisch MS Research Center of New York, the world’s largest independent research center focused on multiple sclerosis, has published groundbreaking new research ...

Here are some of the latest developments in multiple sclerosis (MS) from our sister publication, NeurologyLive®. A recent interview with Kathy M. Zackowski, PhD, OTR, senior director, patient ...

Key opinion leaders discuss the single FDA-approved option for primary progressive multiple sclerosis and emerging therapies under investigation for this MS subtype, examine the PERSEUS trial, and ...

Differences in lesion evolution may help neurologists distinguish between multiple sclerosis (MS) and other demyelinating disorders in new findings that may help explain differences in disease course, ...

I was diagnosed with multiple sclerosis (MS) at 25. When you hear those two words – multiple sclerosis – it changes everything in your life from that day on. After my initial diagnosis, my MS ...